NCT05119972View on ClinicalTrials.gov

Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

December 21, 2023

Study Completion Date

December 21, 2023

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

DRUG

ZSP1603

ZSP1603 administered orally

DRUG

Placebo

Placebo administered orally

Trial Locations (1)

200433

Shanghai Lung Hospital, Shanghai

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT05119972 - Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） | Biotech Hunter | Biotech Hunter